The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investors section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, June 12, 2017.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (
Passcode: 8518262 (Nektar Therapeutics is the host)
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
For Investors and Media:
Jennifer Ruddock of Nektar Therapeutics
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-first-quarter-of-2017-on-tuesday-may-9-2017-after-close-of-us-based-financial-markets-300449323.html
News Provided by Acquire Media